R292K substitution and drug susceptibility of influenza A(H7N9) viruses

Emerg Infect Dis. 2013;19(9):1521-4. doi: 10.3201/eid1909.130724.

Abstract

Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered.

Keywords: H7N9; R292K; antimicrobial resistance; antiviral resistance; avian influenza; influenza; neuraminidase inhibitor; oseltamivir; recombinant neuraminidase; viruses; zanamivir.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Substitution*
  • Antiviral Agents / pharmacology
  • China / epidemiology
  • Disease Outbreaks
  • Drug Resistance, Viral / genetics*
  • Humans
  • Influenza A Virus, H7N9 Subtype / drug effects*
  • Influenza A Virus, H7N9 Subtype / genetics*
  • Influenza, Human / epidemiology
  • Influenza, Human / virology*
  • Microbial Sensitivity Tests
  • Neuraminidase / genetics*
  • Neuraminidase / metabolism

Substances

  • Antiviral Agents
  • Neuraminidase